单选题 公共英语五级
题号 #2539929

回答题:
Text 3
        Shortages of flu vaccine are nothing new in America, but this year' s is a whopper. Until last week, it appeared that 100 million Americans would have access to flu shots this fall. Then British authorities, concerned about quality-control problems at a production plant in Liverpool, barred all further shipments by the Chiron Corp. Overnight, the U. S. vaccine supply dwindled by nearly half and federal health officials found themselves making an unusual plea. Instead of beseeching us all to get vaccinated, they' re now urging most healthy people between the ages of 2 and 64 not to. "This reemphasizes the fragility of our vaccine supply, " says Dr. Martin Myers of the National Net-work for Immunization Information, "and the lack of redundancy in our system. "
        Why is such a basic health service so easily knocked out? Mainly because private companies have had little incentive to pursue it. To create a single dose of flu vaccine, a manufacturer has to grow live virus in a 2-week-old fertilized chicken egg, then crack the egg, harvest the virus and extract the proteins used to provoke an immune response. Profit margins are narrow, demand is fickle and, because each year' s flu virus is different, any leftover vaccine goes to waste. As a result, the United States now has only two major suppliers ( Chiron and Aventis Pasteur)--and when one of them runs into trouble, there isn' t much the other can do about it. "A vaccine maker can' t just call up and order 40 million more fertilized eggs, " says Marion Cox, of Connecticut-based Protein Sciences Corp. "There' s a whole industry that' s scheduled to produce a certain number of eggs at a certain time. "
        Sleeker technologies are now in the works, and experts are hoping that this year' s fiasco will speed the pace of innovation. The main challenge is to shift production from eggs into cell cultures--a medium already used to make most other vaccines. Flu vaccines are harder than most to produce tiffs way, but several biotech companies are now pursuing this strategy, and one culture-based product ( Solvay Pharmaceuticals' Invivac) has been cleared for marketing in Europe.
        For Americans, the immediate challenge is to make the most of a limited supply. The government estimates that 95 million people still qualify for shots under the voluntary restrictions announced last week. That' s nearly twice the number of doses that clinics will have on hand, but only 60 million Americans seek out shots in a normal year. In fact, many experts are hoping the shortage will serve as an awareness campaign---encouraging the people who really need a flu shot to get one.
Shortages of flue vaccine show that ______

进入在线模考

参考答案

D

答案解析

【短文赏析】
        本篇文章探讨了美国流感疫苗短缺事件,经济成因以及当前与未来的解决办法。第一段,作者介绍了美国流感疫苗短缺问题以及其直接原因。由于质量控制等问题,英国当局禁止向美国运输疫苗,从而导致疫苗严重短缺。使疫苗供应量减少了近一半。于是联邦卫生部门的官员敦促2至64岁的健康公民不要注射疫苗;第二段中,作者剖析了其背后的经济原因;在第三段里,作者介绍了解决短缺问题的办法之一:革新疫苗生产技术,将其从受精卵中转移到细胞培养。第四段中,作者探讨了美国的当务之急:如何利用好有限的疫苗。出路就是号召公民发扬风格,将注射疫苗的机会让给敏感群体,让那些真正需要的人能够接种疫苗。
【答案解析】
第一段最后一句话指出了疫苗短缺所暴露出来的问题。“This reemphasizes the fragility of our vaccine supply,”says Dr.Martin Myers of the National Network for Immunization Information.“and the lack of redundancy in Our.system.”“这再次凸显出我们疫苗供应的脆弱性,”全国免疫信息网的马丁·迈尔斯医生说,“此外,我们也没有必要的补救机制。”因此正确答案为D。

你可能感兴趣的试题

A.permitted
B.removed
C.proved
D.produced
A.complicated process, high cost, low profit and high risk
B.shortages of fertilized chicken eggs
C.difficulty in growing live virus
D.fast changing of flu virus
A.the government hopes to solve the problem by way of volunteer restrictions
B.more than 47 million Americans who are qualified to get flu vaccine shots can not get them this year
C.America has to deal with a limited supply of flu vaccines this year
D.normally only a small percentage of American population gets flu vaccine shots each year
找试题 · 找答案 · 找资料 在线模考